A series of year-end results from cannabis-related companies in the US demonstrates the importance of CBD to the bottom line, with volatility in much of the rest of the cannabis and pharmaceutical sectors
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields